A massive transfusion protocol to decrease blood component use and costs

Terence OKeeffe, Majed Refaai, Kathryn Tchorz, John E. Forestner, Ravi Sarode

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Hypothesis: A massive transfusion protocol (MTP) decreases the use of blood components, as well as turnaround times, costs, and mortality. Design: Retrospective before-and-after cohort study. Setting: Academic level I urban trauma center. Patients and Methods: Blood component use was compared in 132 patients during a 2-year period following the implementation of an MTP; 46 patients who were treated the previous year served as historical control subjects. Intervention: Introduction of an MTP that included recombinant factor VIIa for patients with exsanguinating hemorrhage. Main Outcome Measures: The amount of each blood component transfused, turnaround times, blood bank and hospital charges, and mortality rates. Results: After introduction of the MTP, there was a significant decrease in packed red blood cells, plasma, and platelet use. The turnaround time for the first shipment was less than 10 minutes, and the time between the first and second shipments was reduced from 42 to 18 minutes, compared with historical controls. The decreased use of blood products represented a savings of $2270 per patient or an annual savings of $200 000, despite increased costs for recombinant factor VIIa. There was no difference in mortality in either group; it remained around 50%. Thromboembolic complications did not increase, despite a significant increase in the use of recombinant factor VIIa. Conclusions: The MTP resulted in a reduction in the use of blood components with improved turnaround times and significant savings. Mortality was unaffected. The use of recombinant factor VIIa did not increase thromboembolic complications in these patients.

Original languageEnglish (US)
Pages (from-to)686-690
Number of pages5
JournalArchives of Surgery
Volume143
Issue number7
DOIs
StatePublished - Jul 1 2008

Fingerprint

Costs and Cost Analysis
Mortality
Exsanguination
Hospital Charges
Blood Banks
Trauma Centers
Hospital Mortality
Cohort Studies
Blood Platelets
Erythrocytes
Outcome Assessment (Health Care)
recombinant FVIIa

ASJC Scopus subject areas

  • Surgery

Cite this

A massive transfusion protocol to decrease blood component use and costs. / OKeeffe, Terence; Refaai, Majed; Tchorz, Kathryn; Forestner, John E.; Sarode, Ravi.

In: Archives of Surgery, Vol. 143, No. 7, 01.07.2008, p. 686-690.

Research output: Contribution to journalArticle

OKeeffe, Terence ; Refaai, Majed ; Tchorz, Kathryn ; Forestner, John E. ; Sarode, Ravi. / A massive transfusion protocol to decrease blood component use and costs. In: Archives of Surgery. 2008 ; Vol. 143, No. 7. pp. 686-690.
@article{ba1eace193124b28be5d283964e21848,
title = "A massive transfusion protocol to decrease blood component use and costs",
abstract = "Hypothesis: A massive transfusion protocol (MTP) decreases the use of blood components, as well as turnaround times, costs, and mortality. Design: Retrospective before-and-after cohort study. Setting: Academic level I urban trauma center. Patients and Methods: Blood component use was compared in 132 patients during a 2-year period following the implementation of an MTP; 46 patients who were treated the previous year served as historical control subjects. Intervention: Introduction of an MTP that included recombinant factor VIIa for patients with exsanguinating hemorrhage. Main Outcome Measures: The amount of each blood component transfused, turnaround times, blood bank and hospital charges, and mortality rates. Results: After introduction of the MTP, there was a significant decrease in packed red blood cells, plasma, and platelet use. The turnaround time for the first shipment was less than 10 minutes, and the time between the first and second shipments was reduced from 42 to 18 minutes, compared with historical controls. The decreased use of blood products represented a savings of $2270 per patient or an annual savings of $200 000, despite increased costs for recombinant factor VIIa. There was no difference in mortality in either group; it remained around 50{\%}. Thromboembolic complications did not increase, despite a significant increase in the use of recombinant factor VIIa. Conclusions: The MTP resulted in a reduction in the use of blood components with improved turnaround times and significant savings. Mortality was unaffected. The use of recombinant factor VIIa did not increase thromboembolic complications in these patients.",
author = "Terence OKeeffe and Majed Refaai and Kathryn Tchorz and Forestner, {John E.} and Ravi Sarode",
year = "2008",
month = "7",
day = "1",
doi = "10.1001/archsurg.143.7.686",
language = "English (US)",
volume = "143",
pages = "686--690",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "7",

}

TY - JOUR

T1 - A massive transfusion protocol to decrease blood component use and costs

AU - OKeeffe, Terence

AU - Refaai, Majed

AU - Tchorz, Kathryn

AU - Forestner, John E.

AU - Sarode, Ravi

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Hypothesis: A massive transfusion protocol (MTP) decreases the use of blood components, as well as turnaround times, costs, and mortality. Design: Retrospective before-and-after cohort study. Setting: Academic level I urban trauma center. Patients and Methods: Blood component use was compared in 132 patients during a 2-year period following the implementation of an MTP; 46 patients who were treated the previous year served as historical control subjects. Intervention: Introduction of an MTP that included recombinant factor VIIa for patients with exsanguinating hemorrhage. Main Outcome Measures: The amount of each blood component transfused, turnaround times, blood bank and hospital charges, and mortality rates. Results: After introduction of the MTP, there was a significant decrease in packed red blood cells, plasma, and platelet use. The turnaround time for the first shipment was less than 10 minutes, and the time between the first and second shipments was reduced from 42 to 18 minutes, compared with historical controls. The decreased use of blood products represented a savings of $2270 per patient or an annual savings of $200 000, despite increased costs for recombinant factor VIIa. There was no difference in mortality in either group; it remained around 50%. Thromboembolic complications did not increase, despite a significant increase in the use of recombinant factor VIIa. Conclusions: The MTP resulted in a reduction in the use of blood components with improved turnaround times and significant savings. Mortality was unaffected. The use of recombinant factor VIIa did not increase thromboembolic complications in these patients.

AB - Hypothesis: A massive transfusion protocol (MTP) decreases the use of blood components, as well as turnaround times, costs, and mortality. Design: Retrospective before-and-after cohort study. Setting: Academic level I urban trauma center. Patients and Methods: Blood component use was compared in 132 patients during a 2-year period following the implementation of an MTP; 46 patients who were treated the previous year served as historical control subjects. Intervention: Introduction of an MTP that included recombinant factor VIIa for patients with exsanguinating hemorrhage. Main Outcome Measures: The amount of each blood component transfused, turnaround times, blood bank and hospital charges, and mortality rates. Results: After introduction of the MTP, there was a significant decrease in packed red blood cells, plasma, and platelet use. The turnaround time for the first shipment was less than 10 minutes, and the time between the first and second shipments was reduced from 42 to 18 minutes, compared with historical controls. The decreased use of blood products represented a savings of $2270 per patient or an annual savings of $200 000, despite increased costs for recombinant factor VIIa. There was no difference in mortality in either group; it remained around 50%. Thromboembolic complications did not increase, despite a significant increase in the use of recombinant factor VIIa. Conclusions: The MTP resulted in a reduction in the use of blood components with improved turnaround times and significant savings. Mortality was unaffected. The use of recombinant factor VIIa did not increase thromboembolic complications in these patients.

UR - http://www.scopus.com/inward/record.url?scp=47849131979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47849131979&partnerID=8YFLogxK

U2 - 10.1001/archsurg.143.7.686

DO - 10.1001/archsurg.143.7.686

M3 - Article

C2 - 18645112

AN - SCOPUS:47849131979

VL - 143

SP - 686

EP - 690

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 7

ER -